These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1972463)

  • 1. Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate.
    Berntorp E; Nilsson IM; Ljung R; Widell A
    Lancet; 1990 Jun; 335(8704):1531-2. PubMed ID: 1972463
    [No Abstract]   [Full Text] [Related]  

  • 2. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group.
    Mannucci PM; Schimpf K; Brettler DB; Ciavarella N; Colombo M; Haschke F; Lechner K; Lusher J; Weissbach G
    Ann Intern Med; 1990 Jul; 113(1):27-32. PubMed ID: 2112352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels.
    Rumi MG; Colombo M; Gringeri A; Mannucci PM
    Ann Intern Med; 1990 Mar; 112(5):379-80. PubMed ID: 2106281
    [No Abstract]   [Full Text] [Related]  

  • 4. Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate.
    Bergman GE
    Lancet; 1995 Nov; 346(8985):1296-7. PubMed ID: 7475737
    [No Abstract]   [Full Text] [Related]  

  • 5. Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate.
    Kessler C; Lusher J; Pierce GF; Pierce B; Koerper MA; Dickinson JC
    Lancet; 1995 Nov; 346(8985):1297-8. PubMed ID: 7475738
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-hepatitis C antibodies in prospectively followed-up transfused patients.
    Couroucé AM; Jullien AM; Vedrenne JB; Habibi B
    Vox Sang; 1990; 58(3):226-7. PubMed ID: 2111065
    [No Abstract]   [Full Text] [Related]  

  • 7. Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.
    Hollinger FB; Dolana G; Thomas W; Gyorkey F
    J Infect Dis; 1984 Aug; 150(2):250-62. PubMed ID: 6432922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C virus transmission by monoclonal purified viral-attenuated factor VIII concentrate.
    Shopnick RI; Brettler DB; Bolivar E
    Lancet; 1995 Sep; 346(8975):645. PubMed ID: 7651038
    [No Abstract]   [Full Text] [Related]  

  • 10. Transmission of hepatitis C with pasteurised factor VIII.
    Schulman S; Lindgren AC; Petrini P; Allander T
    Lancet; 1992 Aug; 340(8814):305-6. PubMed ID: 1353214
    [No Abstract]   [Full Text] [Related]  

  • 11. [Non-A non-B hepatitis caused by transfusing American antihemophilic globulin (factor VIII) in patients with hemophilia].
    Zhang Z; Li YH; Li XF
    Zhonghua Nei Ke Za Zhi; 1988 Feb; 27(2):82-4, 134. PubMed ID: 3141119
    [No Abstract]   [Full Text] [Related]  

  • 12. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates.
    Garson JA; Tuke PW; Makris M; Briggs M; Machin SJ; Preston FE; Tedder RS
    Lancet; 1990 Oct; 336(8722):1022-5. PubMed ID: 1977017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mother to infant transmission of hepatitis C virus infection.
    Wejstål R; Hermodsson S; Iwarson S; Norkrans G
    J Med Virol; 1990 Mar; 30(3):178-80. PubMed ID: 2111372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody to hepatitis C (anti C 100-3) in French hemophiliacs.
    Maisonneuve P; Laurian Y; Guerois C; Verroust F; Ferrer Le Coeur F; Couroucé AM; Noel L
    Nouv Rev Fr Hematol (1978); 1991; 33(3):263-6. PubMed ID: 1956764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.
    Lusher JM
    Ann Hematol; 1991 Sep; 63(3):138-41. PubMed ID: 1932288
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduced risk of non-A, non-B hepatitis after a first exposure to 'wet heated' factor VIII concentrate.
    Kernoff PB; Miller EJ; Savidge GF; Machin SJ; Dewar MS; Preston FE
    Br J Haematol; 1987 Oct; 67(2):207-11. PubMed ID: 3118932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia.
    Mariani G; Di Paolantonio T; Baklaya R; Morfini M; Mannucci PM
    Transfusion; 1993 Oct; 33(10):814-8. PubMed ID: 8236421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.
    Horowitz MS; Rooks C; Horowitz B; Hilgartner MW
    Lancet; 1988 Jul; 2(8604):186-9. PubMed ID: 2899662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers.
    Everhart JE; Di Bisceglie AM; Murray LM; Alter HJ; Melpolder JJ; Kuo G; Hoofnagle JH
    Ann Intern Med; 1990 Apr; 112(7):544-5. PubMed ID: 1690526
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis and factor VIII concentrates.
    Kernoff PB
    Semin Hematol; 1988 Apr; 25(2 Suppl 1):8-13. PubMed ID: 3133777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.